<?xml version="1.0" encoding="UTF-8"?>
<p>We performed rapid antigen detection using BinaxNOW Influenza A &amp; B Card (Alere, 
 <ext-link ext-link-type="uri" xlink:href="https://www.alere.com" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.alere.com</ext-link>) and determined viral loads by quantitative real-time reverse transcription PCR (RT-PCR) targeting the M gene (
 <xref rid="R5" ref-type="bibr">
  <italic>5</italic>
 </xref>). We performed cell culture using MDCK cells inoculated with the first nasal swab sample; we examined it for cytopathic effect at 72 h. We performed serologic analyses using hemagglutination inhibition (HI) and microneutralization (MN) assays (
 <xref rid="R6" ref-type="bibr">
  <italic>6</italic>
 </xref>,
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>). We determined the complete genome sequencing of the culture isolate by Illumina HiSeq1500 (
 <ext-link ext-link-type="uri" xlink:href="https://www.illumina.com" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.illumina.com</ext-link>) as described previously (
 <xref rid="R8" ref-type="bibr">
  <italic>8</italic>
 </xref>,
 <xref rid="R9" ref-type="bibr">
  <italic>9</italic>
 </xref>). We deposited the genome sequence in the GISAID database (
 <ext-link ext-link-type="uri" xlink:href="http://platform.gisaid.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://platform.gisaid.org</ext-link>; accession no. EPI1493152 and nos. EPI1493160â€“6).
</p>
